Skip to main content
S&P 5007,580.07-1.82%DOW51,770.31-1.09%NASDAQ25,437.00-2.86%BTC$77,595.00-0.42%ETH$2,278.84+0.64%GOLD$3,910.20+0.29%OIL$99.53-4.41%
Smart Investors Daily
SID Premium
OT

NASDAQ · OTLC

Oncotelic Therapeutics, Inc.

Healthcare · Biotechnology

$0.02

Up+$0.00 (+8.11%)

Updated Nov 2, 2026, 1:21 PM

SID Score

3.3/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
39.83M
P/E ratio
-22.99
Dividend yield
0.00%
52-week range
$0.02 – $0.11
Volume
97.73K
Avg. volume
324.47K

Price performance · OTLC

OTLC price history

1M range · 0 trading sessions · Daily adjusted prices

OTLC does not have enough price history for the selected period.

Data unavailable

The requested market data was not found.

Latest OTLC news

The latest Smart Investors Daily articles mentioning OTLC.

Stock researchCompany · Overview

OTLC research

Overview

Company profile and research snapshot.

Company profile

ONCOTELIC THERAPEUTCS INC

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$4.08
Implied upside
—
Analysts
—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 26, 2026

Oncotelic Announces PDAOAI Identification of a Four-Gene Liver Cancer Signature

Study combines AI-guided literature investigation with gene-expression analysis to identify a four-gene signature for Sapu003 development Source: Oncotelic Therapeutics, Inc. AGOURA HILLS, Calif., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC) (“Oncotelic” or the “Company”) today announced the publication of a peer-reviewed study in Biomedicines demonstrating how its AI-powered PDAOAI platform helped identify a four-gene prognostic signature in hepatocellular carcin

Yahoo · Oct 20, 2026

Oncotelic Keynote to Highlight Partition and Aggregation as a Fundamental Principle for AI Enabled Discovery

Saran Saund to connect the emerging research approach with PDAOAI intellectual property, plans for 100 billion biological vectors, individual researcher access through Fastbot/Membot and an HCC case study AGOURA HILLS, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC) (“Oncotelic” or the “Company”) today announced that Chief Business Officer Saran Saund will deliver the opening keynote on Day 2 of the 22nd Drug Discovery Strategic Summit on October 22, 2026. Th

Yahoo · Oct 5, 2026

PDAOAI Opens BIO REBOOT Collaboration and Showcases Partitioned Literature Aggregation at Drug Discovery 2026

Oncotelic’s AI drug discovery platform invites scientists, developers and biotech founders to connect computational discovery with drug development. Source: Oncotelic Therapeutics, Inc. AGOURA HILLS, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC) ("Oncotelic" or the "Company"), together with its wholly owned subsidiary Pet2DAO, Inc. ("Pet2DAO"), today announced that PDAOAI, the Company’s AI-powered drug discovery platform, is inviting scientists, AI develope

Yahoo · Aug 7, 2026

OTCQB Virtual Investor Conference Presentations Now Available for On-Demand Viewing

Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.comNEW YORK, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, announced the presentations from the August 5th & 6th OTCQB Virtual Investor Conference are available for on-demand viewing. The two-day event featured live presentations from executives representing innovative OTCQB-listed companies across the mining, technology, healthcare, infras

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By